[go: up one dir, main page]

SG156668A1 - Angiopoietin-2 specific binding agents - Google Patents

Angiopoietin-2 specific binding agents

Info

Publication number
SG156668A1
SG156668A1 SG200907008-7A SG2009070087A SG156668A1 SG 156668 A1 SG156668 A1 SG 156668A1 SG 2009070087 A SG2009070087 A SG 2009070087A SG 156668 A1 SG156668 A1 SG 156668A1
Authority
SG
Singapore
Prior art keywords
angiopoietin
specific binding
binding agents
antibodies
disclosed
Prior art date
Application number
SG200907008-7A
Inventor
Jonathon Daniel Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG156668A1 publication Critical patent/SG156668A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. No suitable figure
SG200907008-7A 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents SG156668A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
SG156668A1 true SG156668A1 (en) 2009-11-26

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907008-7A SG156668A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Country Status (10)

Country Link
JP (2) JP2008520188A (en)
CN (1) CN101495513B (en)
BR (1) BRPI0518209A (en)
EA (1) EA011866B1 (en)
IL (1) IL182279A0 (en)
MA (1) MA29015B1 (en)
MX (1) MX2007004247A (en)
RU (2) RU2404992C2 (en)
SG (1) SG156668A1 (en)
ZA (1) ZA200704020B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495513B (en) * 2004-10-19 2014-08-06 安姆根有限公司 Angiopoietin-2 specific binding agents
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
EA022546B1 (en) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Method for inhibiting growth of ehrlich carcinoma in laboratory animal
EP3210625B1 (en) * 2011-09-30 2019-08-28 Dana-Farber Cancer Institute, Inc. Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
MY164611A (en) * 2012-01-23 2018-01-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
EP2935294A4 (en) 2012-12-21 2016-08-31 Univ California METHODS AND COMPOSITIONS FOR TREATING THE TOXICITY OF CYANIDE AND HYDROGEN SULFIDE
SG11201509278XA (en) * 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for the production of lanvotinib and its derivatives in a high degree of purity
JP6792546B2 (en) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 How to suppress bitterness of quinoline derivatives
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (en) 2015-08-20 2021-02-19 卫材R&D管理有限公司 Therapeutic agent for tumor
CN106075448A (en) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 ANGPT2 inhibitor is used for treating the application in angiomatous medicine in preparation
CN106512006A (en) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Application of ANGPT2 secretion inhibitor to preparation of medicine for treating hemangiomas
RU2750539C2 (en) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Pharmaceutical composition for treating a tumour
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109096368B (en) * 2018-09-30 2021-07-20 华南理工大学 A polypeptide having both anti-oxidative and liver-protecting activities, a gene encoding the polypeptide, and a preparation method and application thereof
WO2020175886A1 (en) * 2019-02-25 2020-09-03 주식회사 파멥신 Anti-ang2 antibody and use thereof
CN112126671B (en) * 2020-08-18 2021-08-31 中山大学附属第五医院 Application of Streptococcus agalactiae in the treatment of endometriosis
CN116265487B (en) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 Anti-ANG 2-VEGF bispecific antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368670C (en) * 1999-03-26 2012-06-05 Chitra Suri Modulation of vascular permeability by means of tie2 receptor activators
CN1308347C (en) * 1999-04-28 2007-04-04 德克萨斯大学董事会 Compositions and methods for treating cancer by selective inhibition of VEGF
PL359653A1 (en) * 2000-06-23 2004-08-23 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
WO2003030883A1 (en) * 2001-10-12 2003-04-17 Kosmos Pharma Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
CN101495513B (en) * 2004-10-19 2014-08-06 安姆根有限公司 Angiopoietin-2 specific binding agents

Also Published As

Publication number Publication date
EA011866B1 (en) 2009-06-30
RU2010132956A (en) 2012-02-10
MX2007004247A (en) 2007-06-12
RU2007118670A (en) 2008-12-27
JP2008520188A (en) 2008-06-19
CN101495513B (en) 2014-08-06
EA200700876A1 (en) 2007-10-26
ZA200704020B (en) 2008-06-25
JP2011207882A (en) 2011-10-20
BRPI0518209A (en) 2008-11-04
CN101495513A (en) 2009-07-29
RU2404992C2 (en) 2010-11-27
IL182279A0 (en) 2007-07-24
MA29015B1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
SG156668A1 (en) Angiopoietin-2 specific binding agents
LUC00025I1 (en)
SG166090A1 (en) Il-13 binding agents
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EA200400526A1 (en) AGENTS SPECIFICALLY CONNECTING WITH HUMAN ANGIOPOETIN-2
WO2012047583A3 (en) Antibodies binding human collagen ii
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
TW200635946A (en) Binding proteins specific for human matriptase
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
UA94211C2 (en) Isolated fully human monoclonal anti-cd3 antibody
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
MX2007013108A (en) Reagents that bind ccx-ckr2.
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
WO2006013462A3 (en) Growth factors nsg28, nsg30, and nsg32
TN2010000374A1 (en) Antibodies directed to angiopoietin -1 and angiopoietin-2 and use thereof
MX360580B (en) Human anti-alpha-synuclein autoantibodies.